Drug Combination Details
| General Information of the Combination (ID: C22952) | |||||
|---|---|---|---|---|---|
| Name | Withaferin A NP Info | + | Sorafenib Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Thyroid cancer
[ICD-11: 2D10]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Down-regulation | Phosphorylation | CASP3 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | PARP1 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | B-CPAP | CVCL_0153 | Thyroid gland carcinoma | Homo sapiens | ||
| SW1736 | CVCL_3883 | Thyroid gland anaplastic carcinoma | Homo sapiens | |||
| Experimental
Result(s) |
Combination therapy with sorafenib + withaferin showed synergistic efficacy in papillary and anaplastic cancers in vitro with significant induction of apoptosis. | |||||
